Management of anaplastic lymphoma kinase positive orbito-conjunctival inflammatory myofibroblastic tumor with crizotinib.
Inflammatory myofibroblastic tumor (IMT) is a distinct mesenchymal neoplasm of myofibroblastic spindle cells associated with an inflammatory infiltrate formed by lymphocytes, eosinophils, and plasma cells in a myxoid or collagenous stroma. This tumor has a predilection for children and young adults and most commonly occurs in the lungs, retroperitoneum, abdomen, and pelvis. Ocular and orbital involvement is exceedingly rare. We describe a case of IMT in a 7-year-old girl involving the cornea, conjunctiva, and the anterior orbit treated with crizotinib, resulting in complete tumor remission.
Hacettepe University School of Medicine, Sihhiye, Ankara, Turkey. Electronic address: hkiratli@hacettepe.edu.tr.
Hayyam
H
Kiratli
Hacettepe University School of Medicine, Sihhiye, Ankara, Turkey.
Salih
S
Uzun
Hacettepe University School of Medicine, Sihhiye, Ankara, Turkey.
Ali
A
Varan
Hacettepe University School of Medicine, Sihhiye, Ankara, Turkey.
Canan
C
Akyüz
Hacettepe University School of Medicine, Sihhiye, Ankara, Turkey.
Diclehan
D
Orhan
D000284:Administration, Oral; D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D003230:Conjunctival Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D003316:Corneal Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D000077547:Crizotinib; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D058628:Myofibroblasts / Q000473:pathology; D009379:Neoplasms, Muscle Tissue / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D009918:Orbital Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism*
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases